Haldol Drops

Haldol Drops





DCH Auriga - Healthcare
Four Star
Concise Prescribing Info
As a neuroleptic agent in delusions & hallucinations in acute & chronic schizophrenia, paranoia, & acute confusion, alcoholism (Korsakoff's syndrome); hypochondriac delusions; personality disorders: paranoid, schizoid, schizotype, antisocial, some "borderline" & other personalities. As a psychomotor anti-agitation agent in mania, dementia, mental retardation, alcoholism; personality disorders: compulsive, paranoid, histrionic & other personalities; agitation, aggressiveness, & wandering impulsion in the elderly; disorders of behaviour & character in childn; choreatic movements; singultus (hiccup); tics, stuttering. As an adjuvant in the treatment of severe chronic pain. As an anti-emetic in nausea & vomiting of varying origin.
Dosage/Direction for Use
Adult Acute episodes of schizophrenia, delirium tremens, paranoia, acute confusion, Korsakoff's syndrome, acute paranoia Nearly double the IM dose. IM dose: 5-10 mg IM, repeated hrly until sufficient control is achieved or up to max 60 mg/day. Chronic schizophrenia, chronic alcoholism, chronic personality disorders 1-3 mg tds; may be increased to 10-20 mg tds. Chronic phase of mania, dementia, alcoholism, personality disorders, behaviour & character disorders, singultus, choreatic movements, tics, stuttering 0.5-1 mg tds; may be increased to 2-3 mg tds if required. Adjuvant in chronic pain therapy 0.5-1 mg tds. Elderly Initially ½ adult dose, then adjust according to the response if required. Childn 0.1 mg/3 kg tds, may be adjusted if needed.
Hypersensitivity. Comatose state; CNS depression due to alcohol or other depressant drug; Parkinson's disease; lesion of the basal ganglia.
Special Precautions
QT prolongation &/or ventricular arrhythmias; neuroleptic malignant syndrome; tardive dyskinesia on long-term therapy or after drug discontinuation; extrapyramidal symptoms; seizures; hormonal effects ie, hyperprolactinaemia which may cause galactorrhoea, gynaecomastia & oligo- or amenorrhoea; venous thromboembolism. Patients w/ hyperthyroidism. Response to treatment may be delayed in schizophrenia. Recurrence of symptoms may not become apparent for several wk or mth if drugs are withdrawn. Gradual w/drawal is advisable. Should not be used alone where depression is predominant. Patients w/ liver disease. Elderly patients w/ dementia-related psychosis. May affect ability to drive or operate machinery. Pregnancy & lactation.
Adverse Reactions
Extrapyramidal disorder, hyperkinesia, tremor, hypertonia, dystonia, somnolence, bradykinesia, dizziness, akathisia, dyskinesia, hypokinesia, tardive dyskinesia; visual disturbance, oculogyric crisis; constipation, dry mouth, salivary hypersecretion; orthostatic hypotension, hypotension; erectile dysfunction; wt increased.
Drug Interactions
Increased conc w/ CYP3A4 or CYP2D6 inhibitors. Decreased conc w/ enzyme-inducing drugs (eg, carbamazepine, phenobarb, rifampicin). Increased CNS depression w/ other CNS-depressant drugs including alcohol, hypnotics, sedatives or strong analgesics. Enhanced CNS effect w/ methyldopa. Antagonised action of adrenaline & other sympathomimetic agents. Reversed BP-lowering effects of adrenergic-blocking agents eg, guanethidine. May impair antiparkinsonian effects of levodopa. Increased plasma levels of TCAs. Caution when co-administered w/ medications known to prolong QT interval; drugs known to cause electrolyte imbalance. Reports of antagonism of anticoagulant effect of phenindione. Rare reports of encephalopathy, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, brain stem disorder, acute brain syndrome & coma w/ lithium.
MIMS Class
ATC Classification
N05AD01 - haloperidol ; Belongs to the class of butyrophenone derivatives antipsychotics.
Haldol oral drops 2 mg/mL
15 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in